Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIAltO: Ofatumumab-based regimens in less fit CLL patients
2011-000919-22Phase 3Unknown
- Sponsor
- University of Liverpool
- Start
- Sep 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of ofatumumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by University of Liverpool. Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
ofatumumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2011-000919-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000919-22.